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Palamaro et al. describe a child with recurrent bronchopneumonia and very high IgE levels in which a variation,
R156H, was found in the IL12RB1 gene that encodes the IL-12Rβ1 chain. Based on the absence of this variation in
50 unrelated individuals they conclude it is a mutation. We (van de Vosse and van Dissel) feel there is no reason to
suspect a defect in IL-12 signaling based on the clinical data, nor evidence for a functional defect in IL-12 signaling
in this patient. In addition, the variation is not novel and known as a polymorphism. Without any functional
evidence that R156H is a mutation, the current claim is not substantiated.
Palamaro et al. respond to argue that the amino acid substitution, R156H described in the described case exerts a
summatory effect, as a genetic cofactor, along with an additional and still unidentified molecular alteration of the
same pathway.
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We have read with interest the article by Loredana
Palamaro et al. [1] about a child with recurrent bron-
chopneumonia and very high IgE levels in which a muta-
tion was found in the IL12RB1 gene that encodes the
IL-12Rβ1 chain of both the IL-12 and IL-23 receptor.
In individuals with IL-12Rβ1 deficiency, or other deficien-
cies leading to familial atypical mycobacteriosis (OMIM
209950), typically infections with non-tuberculous myco-
bacteria (NTM), and in case of IL-12Rβ1 deficient patients
also non-typhoid salmonellae, are observed. These infec-
tions are often recurrent, difficult to treat, and/or dissemi-
nated throughout the body [2]. Very seldom infections
confined to lung parenchyma are found, and in those cases
mostly Mycobacterium tuberculosis is involved, a pathogen
with a strong preference for the lung. Conversely, in indivi-
duals with NTM lung tissue infections, no defects in the
IL-12/IFN-γ pathway are identified ([3] and personal obser-
vations). Another important feature of IL-12Rβ1 deficiency
is that it is an autosomal recessive disorder, requiring both
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do not have an immunological defect or clinical symptoms.
In the child described in this report no mycobacterial
or salmonellae infections, typical for IL-12Rβ1 defi-
ciency, were found. In addition, the infection was con-
fined to the lung, a tissue normally not affected in these
patients. The high IgE levels that were present in the
child and the family history of allergic disorders are not
a feature seen in IL-12Rβ1 deficiency.
No functional immunological analyses to determine
whether the IL-12/IFN-γ pathway was affected were per-
formed in the child [1]. The only experiment performed
that, at best, provided circumstantial evidence that the
IL12RB1 gene might be affected is the absence of an
IL12RB2 transcript in PBMCs from the patient stimu-
lated, not with a relevant stimulus such as IL-12 or
IL-23, but with a mitogen. Subsequent sequencing of the
IL12RB1 transcript revealed a heterozygous variation,
531G>A, which leads to the amino acid substitution
R156H. The variation was not found in 100 chromo-
somes of unrelated individuals, after which it was con-
cluded that this must be a mutation [1].
The R156H variation in IL-12Rβ1 has been reported
before and is known to be present in 11.3% of North
Americans (4550 chromosomes analysed) and 15% of
Europeans (1285 chromosomes analysed) [4]. An aspect
that may have confused the authors is that the positionentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ATG translation initiation codon, thus designating the
variation found in this child as 467G>A in stead of
531G>A [5]. We have analyzed R156H, as well as several
other amino acid variations in IL-12Rβ1, in a retroviral
expression system and found the R156H variation to be
expressed on the cell membrane and not to have any ef-
fect on IL-12 responses as determined by measuring
IFN-γ and IL-10 production, thus concluding R156H is
most likely a harmless polymorphism [6].
Regardless of the literature provided here, one can
analyze novel variations with the prediction programs
SIFT (sift.jcvi.org/) and Polyphen (genetics.bwh.harvard.
edu/pph2/) to determine whether the substitution is
more likely to be a mutation or a polymorphism.
According to SIFT, which predicts the effect of amino
acid substitutions on the basis of evolutionary conserva-
tion, the R156H variation is tolerated. According to
Polyphen, predicting the possible impact of an amino
acid substitution on the structure and function of a
human protein using straightforward physical and com-
parative considerations, the R156H variation is benign.
In order to, in the future, facilitate finding out whether a
variation is already known to be a mutation, a poly-
morphism or a variation with an unknown effect, a data-
base specific for IL12RB1 variations was recently
launched at: www.LOVD.nl/IL12RB1.
In conclusion, we feel there is no reason to suspect a
defect in IL-12 signaling based on the clinical data, nor
evidence for a functional defect in IL-12 signaling in this
patient. In addition, the variation identified is, based on
various data sources, understood to be a polymorphism.
Without any functional evidence that R156H is a muta-
tion, the current claim is not substantiated.
Reply - Loredana Palamaro, Giuliana Giardino,
Francesca Santamaria, Rosa Romano, Anna Fusco,
Silvia Montella, Mariacarolina Salerno, Matilde
Valeria Ursini and Claudio Pignata
Dear Editor,
In their comment to our case report on a child with
interleukin 12 receptor alteration, van de Vosse and van
Dissel raised the important issue of defining the causa-
tive relationship between a genetic variation and the
phenotypic expression of a clinical entity, stating that
the R156H in IL-12 beta1 receptor chain, reported in
the patient described, is not a mutation but a variation
also present in otherwise healthy individuals.
In principle, we agree with the Authors, in that to de-
fine the R156H allele as causative of the disease may be
considered an overstatement. However, it should be
emphasized that from recent whole genome sequencingstudies, the analysis of the association between genetic
variants and complex traits is establishing as a powerful
strategy to assign a role also to variations otherwise con-
sidered polymorphisms. There are additional examples
of genetic alterations, referred as polymorphisms and,
therefore, with a prevalence in the general population
higher than 1%, which are now considered important
genetic susceptibility factors. The Ala91Val variation of
the perforin gene is present in healthy controls, but is
considered an important genetic element to confer sus-
ceptibility to lymphohistiocytosis [7-9].
In our case report we used the potent mitogen stimu-
lation, which is widely recognized as a trigger of a Th1
polarization, to document the absence of the expression
of the high affinity IL-12 R, consisting of both beta 1
and beta 2 chains. Certainly, a functional evidence of
impaired IL-12 signaling could help to clarify the rela-
tionship between the genetic variation and the clinical
phenotype. Unfortunately, this information is not avail-
able at moment.
As for the molecular analysis, this was performed on
cDNA starting to count from the +1 site. However, this
different enumeration does not interfere with the ami-
noacid substitution, which remains the same as before
(R156H). The important finding of van de Vosse that
this substitution doesn’t affect IL-12 R signaling would
suggest that this variation in our case exerts a summa-
tory effect, as a genetic cofactor, along with an additional
and still unidentified molecular alteration of the same
pathway.
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